Zephyr AI has acquired Aster Insights, gaining access to a longitudinal dataset of over 400,000 cancer patients, enhancing its capabilities in personalized oncology care. The combined data assets aim to accelerate drug development, optimize patient stratification, and enable smarter clinical trials. Concurrently, novel AI-driven methods are emerging for drug-target affinity prediction and machine learning applications in colorectal cancer metabolism, marking significant shifts in oncology research methodologies.